Fiscal Year:
1993
Title:
Pyrromethene Boron Difluorides in PDT
Agency:
HHS
Contract:
N/A
Award Amount:
$50,000.00
Abstract:
The overall objective is to develop new anticancer agents which are cytotoxic in photodynamic therapy (PDT). It has been shown by Morgan and Boyer that pyrromethene boron difluoride (P-BF2) complexes can offer this property. In Phase I, substituted (P-BF2) complexes will be prepared, characterized and evaluated for PDT potentials. Studies have documented that human ovarian cancer cells (LS-2) cultured with the disodium salt of pentamethylpyrromethene-2, 6-disulfonate boron difluoride (PMPDS-BF2) plus exposure to light produced cell growth inhibition. In addition, when PMPDS-BF2 was injected intratumor into the DMBA-rat breast cancer model, followed by exposure to quartz lamp irradiation, 50-100% tumor remissions occurred. Cyano, bistetramethylene and acetoxymethyl substituted P-BF2 complexes will be evaluated in vitro and in vivo in mouse and rat tumor models. The P-BF complexes are considered to be quasiaromatic electron impoverished (QA-eI) heterocycles. They show high extinction coefficients, high fluorescent quantum yields; those with superior laser action poses little to no triplet-triplet absorption in the fluorescence spectral region. These properties will be considered and attempts to associate them to PDT will be made.
Principal Investigator:
Lee Roy Morgan
5044885415
Business Contact:
Small Business Information at Submission:
Dekk-tec, Inc.
3839 Ulloa Street New Orleans, LA 70119
EIN/Tax ID:
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No